Saturday 17 October 2026
Export PTHS’s income statement to Excel — free account
Pelthos Therapeutics Inc.
PTHS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 23.1%, free cash flow fell 1,615.0% and total debt rose 2,692.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.15
0.11
−0.54%
Follow PTHS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.31 | 0.00 | 0.00 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.05) | (5.30) | (9.32) | (5.62) | |
P/B ratio |
0.00 | 3.61 | 1.50 | 1.47 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.41 | 0.00 | 0.00 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.49) | (3.00) | (3.28) | (4.34) | |
EV/FCF |
(3.47) | (2.97) | (3.28) | (4.34) | |
Quick Ratio |
1.22 | 1.76 | 1.03 | 0.90 | |
Current Ratio |
1.98 | 2.79 | 2.05 | 2.01 | |
Net Debt/EBITDA |
(2.89) | (2.94) | (1.24) | 1.00 | |
Debt/Assets |
50.90% | 45.04% | 24.11% | 0.00% | |
Debt/Equity |
(46.58) | 3.40 | 0.81 | 0.00 | |
Asset Turnover |
0.63 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.33 | 0.52 | 0.29 | 0.94 | |
Capex/Depreciation |
0.00 | (0.11) | (0.08) | 0.00 | |
Interest Coverage |
(7.25) | (5.56) | (9.13) | (11.41) | |
Research and Development Expense of Revenue |
3.85% | 1.71% | 3.98% | 1.96% | |
Selling, General and Administrative Expense of Revenue |
177.36% | 193.51% | 196.71% | 265.03% | |
Intangible Assets out of Total Assets |
0.45 | 0.43 | 0.49 | 0.50 | |
Share Based Compensation of Revenue |
17.69% | 17.49% | 19.16% | 37.31% | |
Graham Net Nets |
(0.75) | (0.81) | (0.65) | (0.21) | |
Graham Number |
16.55 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(101.63%) | (130.80%) | (74.55%) | (61.00%) | |
Free Cash Flow Yield |
(42.58%) | (50.84%) | (38.75%) | (19.84%) | |
Revenue per Share |
4.41 | 3.29 | 4.99 | 2.42 | |
Operating CF per Share |
(2.17) | (3.96) | (3.32) | (4.98) | |
Capex per Share |
0.00 | (0.06) | (0.05) | 0.00 | |
Free Cash Flow per Share |
(2.17) | (4.02) | (3.38) | (4.98) | |
Cash per Share |
6.94 | 9.73 | 9.58 | 4.66 | |
Shareholders Equity per Share |
(0.42) | 5.82 | 20.68 | 19.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.42) | 5.82 | 20.68 | 19.03 | |
Free Cash Flow |
(7.67) | (13.32) | (6.35) | (15.26) | |
Working Capital |
31.40 | 44.80 | 27.42 | 24.99 | |
Capital Expenditures |
0.00 | (0.19) | (0.10) | — | |
Net Current Asset Value |
(75.50) | (56.31) | (38.11) | (18.42) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.02 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
5.42 | 4.38 | 2.44 | 3.47 | |
Average Assets |
69.09 | 73.14 | 65.88 | 64.29 | |
Average Common Equity |
(4.00) | 7.54 | 18.08 | 28.41 |
Columns are period end dates